Diagnosing Wet Age-Related Macular Degeneration: Tests, Timing & What to Expect

Understanding Wet AMD

Neovascular (wet) age-related macular degeneration (nAMD) occurs when abnormal choroidal neovascular membranes (CNV) grow beneath the retinal pigment epithelium and leak fluid/blood into the macula, causing rapid central vision distortion and loss. Early diagnosis enables vision-preserving anti-VEGF therapy.

When to Seek Urgent Evaluation

Same-week ophthalmologic assessment if you experience (especially >50 years):

  • New-onset central blurriness or blind spot (scotoma)
  • Metamorphopsia: straight lines appear wavy (door frames, window blinds, text)
  • Diminished color intensity or contrast sensitivity
  • Difficulty recognizing faces or reading despite adequate lighting

Standard Diagnostic Workup

  1. Visual acuity testing (ETDRS or Snellen): Quantifies central vision loss; baseline for treatment monitoring.
  2. Amsler grid (self-monitoring tool): Patient fixates central dot; reports wavy, missing, or distorted lines. Sensitivity ~80% for macular pathology. Home use: test one eye at a time weekly.
  3. Dilated fundus examination (slit-lamp biomicroscopy + 90D/78D lens): Direct visualization of drusen, pigmentary changes, subretinal/intraretinal fluid, hemorrhage, exudates, fibrovascular pigment epithelial detachment (PED).
  4. Optical coherence tomography (OCT) — cornerstone imaging: Non-invasive, micron-resolution cross-sectional retinal scans. Detects subretinal fluid, intraretinal cysts, sub-RPE fluid, PED, hyperreflective exudates. Quantifies central subfield thickness (CST); tracks treatment response. OCT angiography (OCTA) visualizes CNV flow voids without dye.
  5. Fluorescein angiography (FA): Intravenous fluorescein; serial fundus photographs. Identifies CNV leakage pattern (classic vs. occult), size, location relative to fovea. Now primarily for atypical presentations or polypoidal choroidal vasculopathy (PCV) differentiation.
  6. Indocyanine green angiography (ICGA): Near-infrared dye; better choroidal penetration. Essential for diagnosing PCV and retinal angiomatous proliferation (RAP).

Classification Frameworks Guiding Therapy

  • Beckman classification (FA-based): Classic CNV (well-defined early hyperfluorescence) vs. occult CNV (late stippled leakage, serous PED).
  • FLUID criteria (OCT-based): Fluid, location, under/within retina, intraretinal, subretinal—correlates with visual acuity and treatment intervals.

Differential Diagnosis

Central serous chorioretinopathy, macular telangiectasia type 2, diabetic macular edema, retinal vein occlusion, myopic CNV, inflammatory choroidal neovascularization.

Follow-Up Cadence

  • Treatment-naïve: Monthly OCT + acuity during loading phase (typically 3 monthly anti-VEGF injections).
  • Maintenance: Treat-and-extend (progressive interval lengthening) or pro re nata (PRN, as-needed) guided by OCT fluid biomarkers + acuity.
  • Home monitoring: Amsler grid weekly; prompt reporting of changes.

Key takeaway: OCT has revolutionized nAMD management, enabling fluid-driven, personalized treatment regimens that maintain vision in >90% of adherent patients at 2 years. Any sudden central vision change warrants same-week ophthalmic evaluation.

Eye & Vision Disorders - Related Articles